Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether there is any additional benefit from
abciximab administration during percutaneous coronary intervention in patients presenting
with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.
Phase:
Phase 4
Details
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Collaborator:
Technische Universität München
Treatments:
Abciximab Antibodies, Monoclonal Clopidogrel Immunoglobulin Fab Fragments